Research Study

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Principal Investigator 
Haakon Nygaard

Overview

Body Locations and Systems 
Alzheimer's Disease
Disorders and Conditions 
Alzheimer's Disease
ClinicalTrials.gov# 
NCT02167256
Status 
Closed to Recruitment
Study Start/End 
Oct 6, 2015 to Dec 31, 2017
Locations 
UBC Hospital
Name/Title 
Mannie Fan, Research Coordinator
Phone 
604-822-0550
Email Address 
mannie.fan@vch.ca
Purpose of Study 

AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2. Moreover, the investigators have recently shown that a specific SFK, namely Fyn, is aberrantly activated by specific conformations of the Amyloid Beta (Aß) peptide from Alzheimer's disease (AD). Genetic deletion of Fyn rescues AD deficits in preclinical models. This clinical trial will test the potential benefit of AZD0530 for Alzheimer's disease modification.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.